Search

Your search keyword '"Johansen, J. S."' showing total 292 results

Search Constraints

Start Over You searched for: Author "Johansen, J. S." Remove constraint Author: "Johansen, J. S."
292 results on '"Johansen, J. S."'

Search Results

1. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma

2. The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study

4. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

6. Elevated plasma YKL-40 and risk of infectious disease:a prospective study of 94665 individuals from the general population

10. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

17. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

18. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis:a post-hoc study of the OPERA trial

19. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

22. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma

23. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer

24. Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer

25. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

26. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis:post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials

27. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer:a randomized trial (GERICO)

30. Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis:impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

31. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease:Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

32. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer:the ACCORE study

33. Prediction of treatment response to adalimumab:a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

35. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.

36. Study of $^{13}$Be through isobaric analog resonances in the Maya active target

37. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

38. Studies of $\beta$-delayed two-proton emission : The cases of $^{31}$Ar and $^{35}$Ca

40. Plasma IL-6 in early rheumatoid arthritis is associated with disease activity, joint destruction, and treatment response

44. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

45. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality

46. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population

48. SAT0016 Microrna Expression Profiles as Biomarkers for Prediction of Treatment Response to Adalimumab in Patients with Early Rheumatoid Arthritis

49. THU0212 Improved Remission Rates Acquired by Adding Adalimumab to Methotrexate and Intraarticular Glucocorticoid Cannot be Maintained after Withdrawal of Adalimumab. A 2-Year Investigator Initiated Randomised, Controlled Study on Early Rheumatoid Arthritis

Catalog

Books, media, physical & digital resources